K. Lane

发表

Intracranial Hypertension and Cerebral Perfusion Pressure Insults in Adult Hypertensive Intraventricular Hemorrhage: Occurrence and Associations With Outcome.

D. Hanley, I. Awad, C. Thompson, 2019, Critical care medicine.

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

Azam S. Ahmed, Richard E Thompson, B. Jonker, 2019, The Lancet.

The Modified Graeb Score: An Enhanced Tool for Intraventricular Hemorrhage Measurement and Prediction of Functional Outcome

D. Hanley, I. Awad, W. Ziai, 2013, Stroke.

Recanalization following various endovascular modalities for treatment of anterior circulation acute ischemic strokes.

D. Hanley, C. Kase, Nichol McBee, 2012 .

Systemic Hematologic Status Following Intraventricular Recombinant Tissue-Type Plasminogen Activator for Intraventricular Hemorrhage: The CLEAR IVH Study Group

D. Hanley, C. Thompson, W. Ziai, 2011, Stroke.

Enhancing the Informed Consent Process Using Shared Decision Making and Consent Refusal Data from the CLEAR III Trial

D. Hanley, T. Brott, W. Ziai, 2020, Neurocritical Care.

African American Screening and Enrollment in (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III) CLEAR III.

Richard E Thompson, D. Hanley, I. Awad, 2018, Clinical researcher.

Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)

Richard E Thompson, L. Morrison, D. Hanley, 2019, Neurosurgery.

Participation of a coordinating center pharmacy in a multicenter international study.

Steven W Mayo, Nichol McBee, K. Lane, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Bleeding and infection with external ventricular drainage: a systematic review in comparison with adjudicated adverse events in the ongoing Clot Lysis Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III (CLEAR-III IHV) trial.

D. Hanley, C. Kase, I. Awad, 2015, Neurosurgery.

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma

A. Casadevall, B. Lau, D. Hanley, 2021, medRxiv.

How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?

A. Casadevall, D. Hanley, Nichol McBee, 2022, Transfusion.

Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage: The Intraventricular Hemorrhage Thrombolysis Trial

S. Mayer, D. Hanley, A. Marmarou, 2011, Stroke.

The Incidence of Catheter Tract Hemorrhage and Catheter Placement Accuracy in the CLEAR III Trial

Richard E Thompson, D. Hanley, I. Awad, 2018, Neurocritical Care.

Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial.

D. Hanley, R. Narayan, P. Keyl, 2008, Acta neurochirurgica. Supplement.

Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial.

D. Hanley, I. Awad, P. Keyl, 2008, Acta neurochirurgica. Supplement.

Abstracts Presented at the Neurocritical Care Society (NCS) 15th Annual Meeting

Zuccarello, I. Awad, Nichol McBee, 2017, Neurocritical Care.

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

A. Casadevall, B. Lau, D. Hanley, 2022, The New England journal of medicine.

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

D. Hanley, J. Muschelli, P. Vespa, 2017, The Lancet.

Minimally Invasive Surgery Plus Recombinant Tissue-type Plasminogen Activator for Intracerebral Hemorrhage Evacuation Decreases Perihematomal Edema

D. Hanley, J. Muschelli, P. Vespa, 2013, Stroke.

Safety and efficacy of minimally invasive surgery plus recombinant tissue plasminogen activator in intracerebral haemorrhage evacuation (MISTIE): a randomised, phase 2 trial

D. Hanley, J. Muschelli, P. Vespa, 2016, The Lancet Neurology.

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III)

D. Hanley, P. Vespa, C. Kase, 2014, International journal of stroke : official journal of the International Stroke Society.

CSF inflammatory response after intraventricular hemorrhage

D. Hanley, I. Awad, W. Ziai, 2017, Neurology.

Reduced time to imaging, length of stay, and hospital charges following implementation of a novel postoperative pathway for craniotomy.

E. A. Chiocca, K. Lane, O. Arnaout, 2023, Journal of neurosurgery.

Post-Stroke Depression in Patients with Large Spontaneous Intracerebral Hemorrhage.

D. Hanley, I. Awad, W. Ziai, 2021, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials.

D. Hanley, I. Awad, W. Ziai, 2021, Neurosurgery.

Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.

Azam S. Ahmed, M. Malkoff, C. Anderson, 2019, Neurosurgery.

Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial

D. Hanley, I. Awad, K. Lane, 2017, Neurosurgery.

Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial

D. Hanley, J. Muschelli, P. Vespa, 2016, The Lancet Neurology.

ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain Hemorrhage: A Multicenter Randomized Controlled Trial

J. Engh, D. Hanley, P. Vespa, 2016, Stroke.

Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.

L. Morrison, D. Hanley, R. Shenkar, 2018, Neurosurgery.

Occurrence and impact of intracranial pressure elevation during treatment of severe intraventricular hemorrhage*

D. Hanley, I. Awad, C. Thompson, 2012, Critical care medicine.

Factors Affecting Clot Lysis Rates in Patients With Spontaneous Intraventricular Hemorrhage

D. Hanley, J. Muschelli, C. Thompson, 2012, Stroke.

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

A. Casadevall, A. Dietz, D. Hanley, 2022, Blood Advances.

Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage

J. Ulatowski, K. Lane, G. Sung, 2000, Critical care medicine.

Early Treatment, Inflammation and Post-COVID Conditions

David M. Shade, A. Casadevall, O. Laeyendecker, 2023, medRxiv.

Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III) A Posthoc Root-Cause Analysis

D. Hanley, I. Awad, W. Ziai, 2018, Neurosurgery.

Thrombolysis Trial Resolution in Brain Hemorrhage : The Intraventricular Hemorrhage Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot

S. Mayer, D. Hanley, A. Marmarou, 2011 .

A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III)

C. Anderson, D. Hanley, P. Vespa, 2019, International journal of stroke : official journal of the International Stroke Society.

Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations

A. Casadevall, B. Lau, L. Appel, 2023, medRxiv.

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection

A. Casadevall, B. Lau, L. Appel, 2021, medRxiv.

Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling

B. Hart, H. Sair, R. Shenkar, 2023, medRxiv.

Mechanisms to expedite pediatric clinical trial site activation: The DOSE trial experience.

M. A. Sellers, K. Lane, P. Smith, 2022, Contemporary clinical trials.

Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms

S. Zeiler, M. Saheed, K. Lane, 2018, PloS one.

Early Therapy Intensity Level (TIL) Predicts Mortality in Spontaneous Intracerebral Hemorrhage

D. Hanley, W. Ziai, N. Ullman, 2015, Neurocritical Care.

Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage

J. Ulatowski, K. Lane, G. Sung, 2018 .

Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learned

Terri L. Edwards, K. Wiley, K. Lane, 2023, Journal of Clinical and Translational Science.

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern

A. Casadevall, A. Dietz, O. Laeyendecker, 2022, medRxiv.

Response of the trial innovation network to the COVID-19 pandemic

Terri L. Edwards, G. Bernard, K. Lane, 2021, Journal of Clinical and Translational Science.

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

J. Muschelli, P. Vespa, H. Adams, 2017, The Lancet.

Early antibody treatment, inflammation, and risk of post-COVID conditions

L. Hammitt, K. Lane, A. Pekosz, 2023, mBio.

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling

B. Hart, R. Shenkar, I. Awad, 2023, Stroke.

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome

B. Hart, R. Shenkar, I. Awad, 2023, Stroke.

Erratum for Gebo et al., “Early antibody treatment, inflammation, and risk of post-COVID conditions”

L. Hammitt, K. Lane, A. Pekosz, 2023, mBio.

Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials

David M. Shade, A. Casadevall, B. Lau, 2023, Transfusion.